FDA Fast-Tracks Potential First Drug for Rare Lung Disease

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

LANGHORNE, Pa.--(BUSINESS WIRE)--Feb 20, 2026-

FDA fast-tracks potential first drug for rare lung disease

Priority FDA review sets Aug. 22, 2026 target for Savara’s MOLBREEVI in autoimmune PAP, a rare lung disease, with EU and UK filings due by Q1 2026.